Try our Advanced Search for more refined results

In Re: Celexa and Lexapro Marketing and Sales Practices Litigation

  1. January 29, 2018

    Forest Beats Final Cases In Celexa, Lexapro MDL

    Forest Laboratories Inc. prevailed on Monday against claims by a health and benefit fund and a pair of mothers that it fraudulently promoted Celexa and Lexapro for pediatric depression, putting long-running Massachusetts multidistrict litigation against the company to rest.

  2. January 03, 2018

    Drug Buyers Can't Get Forest Labs Docs Related To Probe

    A Massachusetts federal judge on Tuesday ruled Forest Laboratories can't be forced to produce documents from a congressional probe into the use of antidepressants in children, rejecting objections from parents accusing the company of fraudulently promoting Celexa and Lexapro for pediatric depression.

  3. October 16, 2017

    FDA Finding Doesn't Absolve Forest Labs, Parents Say

    Parents who bought antidepressants for their children urged a Massachusetts federal court on Friday to keep alive multidistrict litigation alleging Forest Laboratories LLC fraudulently promoted Celexa and Lexapro to treat pediatric depression, saying the FDA's finding that one treatment study was promising doesn't rule out other, contradictory evidence.

  4. September 18, 2017

    Forest Labs Seeks Quick Win In Celexa, Lexapro MDL

    Forest Laboratories LLC urged a Massachusetts federal court Friday to dismiss claims in multidistrict litigation alleging the company fraudulently promoted antidepressants Celexa and Lexapro to treat pediatric depression, saying the parties haven't established injury or causation under the Racketeer Influenced and Corrupt Organizations Act.

  5. August 15, 2017

    Judge Denies Consumers Cert. In Celexa, Lexapro MDL

    A Massachusetts federal judge declined to certify a class of consumers in multidistrict litigation accusing Forest Laboratories of fraudulently promoting Celexa and Lexapro as treatments for pediatric depression, citing individual analyses that would be required to determine issues around the drugs' use and promotion.

  6. February 28, 2017

    Health Care Fund Seeks Class Cert. In Celexa, Lexapro MDL

    A health care fund asked a Massachusetts federal judge on Tuesday to certify a class of health benefit providers in multidistrict litigation accusing Forest Laboratories of misleading consumers about whether Celexa and Lexapro could treat pediatric depression, saying evidence that efficacy studies were compromised backed its classwide Racketeer Influenced and Corrupt Organizations Act claim.

  7. June 09, 2016

    Potential Class Action Can Proceed In Celexa, Lexapro MDL

    A Massachusetts federal judge on Thursday refused to dismiss a potential class action accusing Forest Laboratories Inc. in multidistrict litigation of misleading consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression, finding a mother properly alleged plausible Racketeer Influenced and Corrupt Organizations Act claims.

  8. June 02, 2016

    Forest Escapes Class Cert. In Antidepressant Marketing MDL

    A Massachusetts federal judge on Thursday concluded that individual questions of causation and injury outweigh certification of a proposed class of third-party payors accusing Forest Laboratories Inc. in multidistrict litigation of misleading consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression.

  9. May 09, 2016

    Health Care Funds Push For Class Cert. In Celexa Drug MDL

    Health care fund providers seeking to recover money lost because of Forest Laboratories' allegedly fraudulent promotion of its drugs in treating pediatric depression pressed a Massachusetts federal judge to certify their portion of the multidistrict litigation as a class, saying previous court rulings and common issues called for it.

  10. February 29, 2016

    Forest Fights Class Claims In Antidepressant Marketing MDL

    Forest Laboratories on Friday struck back in multidistrict litigation alleging it misled consumers about the efficacy of its drugs Celexa and Lexapro in treating pediatric depression, telling a Massachusetts federal court the class claims of a pair of consumers are too individualized to be decided classwide.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!